490 related articles for article (PubMed ID: 19819315)
1. Gelatin nanocarriers as potential vectors for effective management of tuberculosis.
Saraogi GK; Gupta P; Gupta UD; Jain NK; Agrawal GP
Int J Pharm; 2010 Jan; 385(1-2):143-9. PubMed ID: 19819315
[TBL] [Abstract][Full Text] [Related]
2. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis.
Saraogi GK; Sharma B; Joshi B; Gupta P; Gupta UD; Jain NK; Agrawal GP
J Drug Target; 2011 Apr; 19(3):219-27. PubMed ID: 20540651
[TBL] [Abstract][Full Text] [Related]
3. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
Singh H; Jindal S; Singh M; Sharma G; Kaur IP
Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
[TBL] [Abstract][Full Text] [Related]
4. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.
Ye J; Wang Q; Zhou X; Zhang N
Int J Pharm; 2008 Mar; 352(1-2):273-9. PubMed ID: 18054182
[TBL] [Abstract][Full Text] [Related]
5. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
6. Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nano-particles.
Saxena A; Sachin K; Bohidar HB; Verma AK
Colloids Surf B Biointerfaces; 2005 Sep; 45(1):42-8. PubMed ID: 16112559
[TBL] [Abstract][Full Text] [Related]
7. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.
Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
Mol Pharm; 2015 Nov; 12(11):3839-50. PubMed ID: 26436948
[TBL] [Abstract][Full Text] [Related]
8. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.
Booysen LL; Kalombo L; Brooks E; Hansen R; Gilliland J; Gruppo V; Lungenhofer P; Semete-Makokotlela B; Swai HS; Kotze AF; Lenaerts A; du Plessis LH
Int J Pharm; 2013 Feb; 444(1-2):10-7. PubMed ID: 23357255
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
[TBL] [Abstract][Full Text] [Related]
10. Gelatin microspheres of rifampicin cross-linked with sucrose using thermal gelation method for the treatment of tuberculosis.
Samad A; Sultana Y; Khar RK; Chuttani K; Mishra AK
J Microencapsul; 2009 Feb; 26(1):83-9. PubMed ID: 18608799
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of nanoparticles of glibenclamide by solvent displacement method.
Dora CP; Singh SK; Kumar S; Datusalia AK; Deep A
Acta Pol Pharm; 2010; 67(3):283-90. PubMed ID: 20524431
[TBL] [Abstract][Full Text] [Related]
12. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery.
Jain SK; Gupta Y; Jain A; Saxena AR; Khare P; Jain A
Nanomedicine; 2008 Mar; 4(1):41-8. PubMed ID: 18207463
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of rifampicin loaded floating microspheres.
Goyal P; Gill S; Gupta UD; Rath G; Narang RK; Goyal AK
Artif Cells Blood Substit Immobil Biotechnol; 2011 Oct; 39(5):330-4. PubMed ID: 21631389
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2006 May; 27(5):409-16. PubMed ID: 16624533
[TBL] [Abstract][Full Text] [Related]
16. Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain.
Pillay S; Pillay V; Choonara YE; Naidoo D; Khan RA; du Toit LC; Ndesendo VM; Modi G; Danckwerts MP; Iyuke SE
Int J Pharm; 2009 Dec; 382(1-2):277-90. PubMed ID: 19703530
[TBL] [Abstract][Full Text] [Related]
17. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
[TBL] [Abstract][Full Text] [Related]
19. Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses.
Madan J; Dhiman N; Sardana S; Aneja R; Chandra R; Katyal A
Anticancer Drugs; 2011 Jul; 22(6):543-55. PubMed ID: 21471809
[TBL] [Abstract][Full Text] [Related]
20. Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin.
Li L; Gao FP; Tang HB; Bai YG; Li RF; Li XM; Liu LR; Wang YS; Zhang QQ
Nanotechnology; 2010 Jul; 21(26):265601. PubMed ID: 20522924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
